Results 211 to 220 of about 77,925 (341)

Atomic Scale Origin of Metal Ion Release from Hip Implant Taper Junctions

, 2020
Gilbert J., Gilbert J. L., Liu Y., Narushima T., Pourbaix M., Saleski W. J., Weiss I., Zum Gahr K. H.   +7 more
core   +1 more source

New biosensors and transgenic mice for multiplex cGMP imaging

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a versatile second messenger that is important for human (patho‐)physiology and pharmacotherapy. Live‐cell imaging of cGMP with biosensors allows to elucidate its spatiotemporal dynamics in real time under close‐to‐native conditions. However, to monitor two separate cGMP pools or cGMP/cAMP
Markus Wolters, Martin Thunemann, Barbara Birk, Susanne Feil, Viacheslav O. Nikolaev, Moritz Lehners, Robert Feil   +6 more
wiley   +1 more source

PDE4D and PDE3B orchestrate distinct cAMP microdomains in 3T3‐L1 adipocytes

British Journal of Pharmacology, EarlyView.
Basal conditions: •Ins/PDE3B lowers cytoplasmic cAMP (cyt‐cAMP) without affecting plasma membrane cAMP (pm‐cAMP). •Insulin decreases lipid droplet cAMP (LD‐cAMP) independent of PDE3B. •FGF1/PDE4D modestly reduces both cyt‐ and pm‐cAMP, while PDE4D alone can modulate LD‐cAMP. ISO stimulation: •Ins/PDE3B has minimal impact on cyt‐cAMP.
Johannes Krier, David Spähn, David Arturo Juarez Lopez, Judith L. Nono, Judith Seigner, Lisa Jacob, Siegfried Ussar, Robert Lukowski, Andreas L. Birkenfeld, Gencer Sancar   +9 more
wiley   +1 more source

Fretting Wear Behaviors of Silicone Rubber under Dry Friction and Different Lubrication Conditions. [PDF]

Materials (Basel)
Liu R, Su J, Zhang T, Ke L.
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Imaging and speciation of intracellular metallic implant debris using synchrotron-based X-ray fluorescence micro-spectroscopy: a study of two cases. [PDF]

Sci Rep
Liu S, Chen S, Lai B, Antipova O, Luo Y, Hall DJ, Jin Q, Maxey E, Jacobs JJ, Pourzal R.   +9 more
europepmc   +1 more source

Targeting hexokinase 2 to induce breast cancer cell senescence

British Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof, Katarina Cisarova, Sandra Burgstaller, Mia Schwerer, Markus Absenger‐Novak, Philipp J. Jost, Roland Malli, Wolfgang F. Graier, Robert Lukowski   +8 more
wiley   +1 more source

Assessment of Radiographic Image Texture in the Maxilla and Mandible Around Titanium Inserts Used for Osteosynthesis of Dentofacial Deformities. [PDF]

J Funct Biomater
Antonowicz B, Borowska M, Łukaszuk K, Woźniak Ł, Zalewska A, Distefano A, Borys J.   +6 more
europepmc   +1 more source

Finite element analysis of fretting fatigue of fretted wires [PDF]

, 2015
Abdel Wahab, Magd, Li, XW, Mao, XB, Wang, DG, Wang, LL, Zhang, DK, Zhu, ZC   +6 more
core   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source